サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1701316

フォンダパリヌクスの市場規模、シェア、動向分析レポート：タイプ別、製品別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Fondaparinux Market Size, Share & Trends Analysis Report By Type (Deep Vein Thrombosis), By Product (Branded, Generic), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
フォンダパリヌクスの市場規模、シェア、動向分析レポート：タイプ別、製品別、流通チャネル別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年03月03日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

フォンダパリヌクス市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のフォンダパリヌクス市場規模は2030年までに9億9,090万米ドルに達すると推定され、2025～2030年にかけて6.3%のCAGRで成長する見込みです。

フォンダパリヌクスは主に膝関節置換術や股関節置換術の際に使用されます。GSKグループが製造するアリクストラはフォンダパリヌクスのブランド薬です。この薬は2002年に特許が切れました。この活性分子は製造が非常に複雑であるため、2011年までジェネリック医薬品の競合は少なかりました。アルケミア社やアポテックス社などのジェネリックメーカー各社は2011年に簡略新薬承認を取得し、即座にジェネリック医薬品の製造を開始しました。

フォンダパリヌクスは抗凝固剤として使用され、低分子ヘパリンと比較して生存率の向上を示しています。深部静脈血栓症（DVT）と肺塞栓症（PE）の予防に使用され、皮下投与されます。さらに、フォンダパリヌクスは虚血イベントのリスクを低下させています。

特許技術によって分子を製造するための知的財産権（IPR）を取得するための主要参入企業間の協力の増加は、成長を促進すると予想されます。例えば、2016年7月にDr. Reddy's Laboratories Ltd.はAlchemia Ltd.とフォンダパリヌクスナトリウムのIPRを1,750万米ドルで購入する契約を締結しました。2014年9月、Mylan N.V.はフォンダパリヌクスナトリウムの先発品と後発品をアスペン・世界社から2億2,500万米ドルで購入しました。この取引により、マイランN.V.は、PE治療に適応のある2つのジェネリック医薬品のうちの1つを入手できるようになりました。

フォンダパリヌクス市場レポートハイライト

  • ジェネリック医薬品は2024年に52.1%の最大売上シェアを占め、予測期間中もその優位性を維持すると予想されます。
  • 深部静脈血栓症（DVT）セグメントは2024年に市場の主要シェアを占めます。
  • 2024年、病院薬局がフォンダパリヌクスの主要流通チャネルに浮上
  • 北米のフォンダパリヌクス市場は世界市場を独占し、2024年には37.6％の最大売上シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 フォンダパリヌクス市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 フォンダパリヌクス市場：タイプビジネス分析

  • タイプ市場シェア、2024年と2030年
  • タイプセグメントダッシュボード
  • 市場規模、予測、動向分析（タイプ別、2018～2030年）
  • 深部静脈血栓症
  • 肺塞栓症

第5章 フォンダパリヌクス市場：製品ビジネス分析

  • 製品市場シェア、2024年と2030年
  • 製品セグメントダッシュボード
  • 市場規模、予測、動向分析（製品別、2018～2030年）
  • ブランド
  • ジェネリック

第6章 フォンダパリヌクス市場：流通チャネルビジネス分析

  • 流通チャネル市場シェア、2024年と2030年
  • 流通チャネルセグメントダッシュボード
  • 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 フォンダパリヌクス市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 国別、2018～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 国別、2018～2030年
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • 国別、2018～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Abbott Laboratories Inc.
    • Alchemia Limited
    • Apotex Inc.
    • GSK plc
    • Lupin Pharmaceuticals, Inc
    • ScinoPharm Taiwan Ltd
    • Dr. Reddy's Laboratories Ltd.
    • Bayer Healthcare AG
    • GlaxoSmithKline
    • Boehringer Ingelheim
    • Sanofi
    • WisMed
    • Kaifeng
    • Mylan
図表

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Fondaparinux Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 5 Global Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 6 Global Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Fondaparinux Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 North America Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 10 North America Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 13 U.S. Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 16 Canada Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 19 Mexico Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Fondaparinux Market, By Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 23 Europe Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 UK Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 25 UK Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 26 UK Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 29 Germany Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 France Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 31 France Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 32 France Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Italy Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 38 Spain Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Denmark Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 40 Denmark Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 41 Denmark Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Sweden Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 43 Sweden Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 44 Sweden Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Norway Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 46 Norway Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 47 Norway Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Fondaparinux Market, By Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Japan Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 54 Japan Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 China Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 56 China Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 57 China Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 India Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 India Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 60 India Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Australia Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 62 Australia Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 63 Australia Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 65 South Korea Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 66 South Korea Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 68 Thailand Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 69 Thailand Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America Fondaparinux Market, By Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 72 Latin America Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 73 Latin America Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 76 Brazil Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 78 Argentina Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 79 Argentina Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Fondaparinux Market, By Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 85 South Africa Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 86 South Africa Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 UAE Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 91 UAE Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 92 UAE Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Fondaparinux Market, By Type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Fondaparinux Market, By Product, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Fondaparinux Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Fondaparinux Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Type and Product Outlook (USD Million)
  • Fig. 10 Distribution Channel Outlook (USD Million)
  • Fig. 11 Competitive Landscape
  • Fig. 12 Fondaparinux Market Dynamics
  • Fig. 13 Fondaparinux Market: Porter's Five Forces Analysis
  • Fig. 14 Fondaparinux Market: PESTLE Analysis
  • Fig. 15 Fondaparinux Market: Type Segment Dashboard
  • Fig. 16 Fondaparinux Market: Type Market Share Analysis, 2024 & 2030
  • Fig. 17 Deep Vein Thrombosis Market, 2018 - 2030 (USD Million)
  • Fig. 18 Pulmonary Embolism Market, 2018 - 2030 (USD Million)
  • Fig. 19 Fondaparinux Market: Product Segment Dashboard
  • Fig. 20 Fondaparinux Market: Product Market Share Analysis, 2024 & 2030
  • Fig. 21 Branded Market, 2018 - 2030 (USD Million)
  • Fig. 22 Generic Market, 2018 - 2030 (USD Million)
  • Fig. 23 Fondaparinux Market: Distribution Channel Segment Dashboard
  • Fig. 24 Fondaparinux Market: Distribution Channel Market Share Analysis, 2024 & 2030
  • Fig. 25 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 26 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 27 Online Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 28 Fondaparinux Market Revenue, By Region
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 Regional Marketplace: Key Takeaways
  • Fig. 31 North America Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Country Dynamics
  • Fig. 33 U.S. Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Country Dynamics
  • Fig. 35 Canada Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico Country Dynamics
  • Fig. 37 Mexico Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 39 UK Country Dynamics
  • Fig. 40 UK Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 41 Germany Country Dynamics
  • Fig. 42 Germany Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 43 France Country Dynamics
  • Fig. 44 France Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 45 Italy Country Dynamics
  • Fig. 46 Italy Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain Country Dynamics
  • Fig. 48 Spain Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway Country Dynamics
  • Fig. 50 Norway Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden Country Dynamics
  • Fig. 52 Sweden Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark Country Dynamics
  • Fig. 54 Denmark Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan Country Dynamics
  • Fig. 57 Japan Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 58 China Country Dynamics
  • Fig. 59 China Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 60 India Country Dynamics
  • Fig. 61 India Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia Country Dynamics
  • Fig. 63 Australia Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea Country Dynamics
  • Fig. 65 South Korea Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand Country Dynamics
  • Fig. 67 Thailand Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil Country Dynamics
  • Fig. 70 Brazil Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina Country Dynamics
  • Fig. 72 Argentina Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 73 MEA Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa Country Dynamics
  • Fig. 75 South Africa Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia Country Dynamics
  • Fig. 77 Saudi Arabia Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE Country Dynamics
  • Fig. 79 UAE Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 80 Kuwait Country Dynamics
  • Fig. 81 Kuwait Fondaparinux Market, 2018 - 2030 (USD Million)
  • Fig. 82 Company Categorization
  • Fig. 83 Company Market Position Analysis
  • Fig. 84 Strategic Framework
目次
Product Code: 978-1-68038-960-9

Fondaparinux Market Growth & Trends:

The global fondaparinux market size is estimated to reach USD 990.9 million by 2030, registering to grow at a CAGR of 6.3% from 2025 to 2030 according to a new report by Grand View Research, Inc. Fondaparinux is majorly used during knee and hip replacement surgeries. Arixtra, manufactured by GSK group of companies is the branded drug of Fondaparinux. The drug witnessed patent expiry in 2002. As the active molecule is highly complex to manufacture, it faced low generic competition until 2011. Generic manufacturer companies, such as Alchemia Ltd. and Apotex, Inc., received the Abbreviated New Drug Application approval in 2011 and instantly started the production of generic drugs.

Fondaparinux is used as an anticoagulant and shows improved survival compared with low-molecular-weight heparin. It is used for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is administered subcutaneously. Moreover, Fondaparinux lowers the risk of ischemic events

The increasing collaboration between the key players for acquiring the Intellectual Property Rights (IPRs) in order to manufacture the molecule through patented technology is expected to drive growth. For instance, in July 2016 Dr. Reddy's Laboratories Ltd. entered into an agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium for USD 17.5 million. In September 2014, Mylan N.V. purchased branded and generic versions of fondaparinux sodium from Aspen Global, Inc. for USD 225 million. The deal gave Mylan N.V. access to one of the two generics indicated for the treatment of PE.

Fondaparinux Market Report Highlights:

  • The generic segment accounted for the largest revenue share of 52.1% in 2024 and is expected to maintain its dominance during the forecast period.
  • The Deep Vein Thrombosis (DVT) segment accounted for a leading share of the market in 2024.
  • Hospital pharmacies emerged as the leading distribution channel for fondaparinux in 2024
  • North America fondaparinux market dominated the global market and accounted for the largest revenue share of 37.6% in 2024

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Fondaparinux Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Fondaparinux Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Deep Vein Thrombosis
    • 4.4.1. Deep Vein Thrombosis Market, 2018 - 2030 (USD Million)
  • 4.5. Pulmonary Embolism
    • 4.5.1. Pulmonary Embolism Market, 2018 - 2030 (USD Million)

Chapter 5. Fondaparinux Market: Product Business Analysis

  • 5.1. Product Market Share, 2024 & 2030
  • 5.2. Product Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 5.4. Branded
    • 5.4.1. Branded Market, 2018 - 2030 (USD Million)
  • 5.5. Generic
    • 5.5.1. Generic Market, 2018 - 2030 (USD Million)

Chapter 6. Fondaparinux Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Fondaparinux Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Australia Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. South Korea Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Fondaparinux Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Fondaparinux Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Abbott Laboratories Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Alchemia Limited
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Apotex Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. GSK plc
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Lupin Pharmaceuticals, Inc
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. ScinoPharm Taiwan Ltd
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Dr. Reddy's Laboratories Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives.
    • 8.5.8. Bayer Healthcare AG
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. GlaxoSmithKline
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Boehringer Ingelheim
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Sanofi
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. WisMed
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Kaifeng
      • 8.5.13.1. Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. Mylan
      • 8.5.14.1. Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Product Benchmarking
      • 8.5.14.4. Strategic Initiatives